Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2026)

Aquestive Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $4.4 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 78.58% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $86.4 million, a 284.02% increase from a year earlier, with the FY2025 full-year figure at $102.6 million, up 22.76% from the prior year.
• Cash from Financing Activities climbed to $4.4 million in Q1 2026 per AQST's latest filing, from $660000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $81.7 million in Q1 2024 and bottomed at -$9.2 million in Q1 2023.
• The 5-year median for Cash from Financing Activities is $1.7 million (2024), against an average of $12.1 million.
• Across the five-year window, Cash from Financing Activities sank 809.17% in 2023 and surged 478988.24% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $234000.0 in 2022, then surged by 1572.22% to $3.9 million in 2023, then plunged by 95.99% to $157000.0 in 2024, then surged by 320.38% to $660000.0 in 2025, then jumped by 570.15% to $4.4 million in 2026.
• Per Business Quant, the three latest AQST Cash from Financing Activities figures stand at $4.4 million (Q1 2026), $660000.0 (Q4 2025), and $81.4 million (Q3 2025).